Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 4 7Phase 3 7Phase 1/2 6Phase 2/3 3Phase NA 2Phase 1 2

Status

Completed 3Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Vasculitis 1Metabolic Syndrome 1Inflammation 1Granulomatosis with Polyangiitis 1Arthritis, Juvenile 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Etanercept × Clear all
NCT03780959 2019-08-02

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

Amgen

Phase 2/3 Completed
69 enrolled 11 charts

Arthritis, Juvenile

NCT00111956 2017-10-06

Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2/3 Completed
56 enrolled

Inflammation, Metabolic Syndrome

NCT00005007 2007-12-28

Etanercept for Wegener's Granulomatosis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Phase 2/3 Completed
181 enrolled

Vasculitis, Granulomatosis with Polyangiitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡